Shaping the Future of Cancer Science and Patient Care, Together
Dana-Farber Cancer Institute has a strong legacy of innovation in cancer science and extraordinary patient care. As we establish the Dana-Farber Beth Israel Deaconess Cancer Collaboration, including a proposed future inpatient cancer hospital, we understand current and future supporters of Dana-Farber will have questions about how this change may impact contributions to our programs and initiatives.
Common Questions About Supporting Our New Collaboration
Will donations to Dana-Farber fund BIDMC programs?
Even as we create this new collaboration, Dana-Farber and BIDMC fundraising will remain fully independent. All philanthropic contributions to Dana-Farber will continue to fund Dana-Farber initiatives.
Will my donor information be shared between the two organizations?
Donor information will be kept confidential at each institution; if you already support both organizations, each hospital will be aware of your information.
Does the focus on an inpatient building signal a shift away from research?
No. Our unique equal focus on patient care and research will remain the same; in structuring this new relationship with BIDMC, we also expect to expand advancements in scientific discovery that will lead to transformative new treatments. The proximity of the proposed inpatient hospital to our outpatient and research facilities in the Longwood Medical Area, Boston, and surrounding communities, supports our continued efforts of bench-to-bedside research.
I am a Pan-Mass Challenge rider/fundraiser; how will this impact me?
We are deeply grateful for the support of the Pan-Mass Challenge (PMC) community. Gifts raised in support of Dana-Farber through the PMC will continue to support the Institute without any changes. Since 1980, the PMC has raised more than $1 billion for Dana-Farber. We hope that you share our excitement about this dynamic new model.
Were any funds raised through The Dana-Farber Campaign allocated to fund the proposed Future Cancer Hospital?
No. On September 30, 2024, Dana-Farber Cancer Institute announced the completion of The Dana-Farber Campaign, a seven-year initiative to accelerate the Institute’s strategic priorities supporting a wide range of programs and people that are at the center of providing evolutionary science and extraordinary care at Dana-Farber. Gifts to the campaign funded clinical trials, addressed increased patient volume and cancer diagnoses, and supported prevention, early detection, and interception, among other groundbreaking initiatives.
With this collaboration, we have an important opportunity to create a new inpatient facility dedicated entirely to the needs of the adult cancer patient. We look forward to sharing more details about the design and construction of this new facility in the near future.
I am a patient and a donor. Where can I find more information about my patient care?
There will be no changes in patient care for several years. Get regular updates and answers to common questions for patients and caregivers.
